Biota Holdings (BTA) Short Interest
Biota Holdings (ASX:BTA) had 1.87% of shares reported as short positions as of 12 Nov 2012, representing 3,508,047 shares. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Biota Holdings
Biota Holdings was an Australian biotechnology company renowned for its pioneering work in antiviral drug discovery, particularly the development of zanamivir, which became the influenza drug Relenza. The company's business model focused on identifying and developing novel drug candidates, primarily in the antiviral space, and then out-licensing them to larger pharmaceutical partners for commercialization. Biota played a significant role in the global fight against influenza through its innovative research.
Short position
Biota Holdings (ASX:BTA) has 1.87% of its shares on issue reported as short positions as of 12 Nov 2012, or about 3,508,047 shares. Over the past 30 days that figure has risen 1.17 percentage points, and over 90 days it has risen 1.54 percentage points. Its highest recorded short interest was 2.66% in October 2012. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4BTA intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Biota Holdings
About
website
Be the first to discuss BTA
Start a research thread or post the first pulse update